Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

GLG News by Physicians who Treat Dry Eye (US)

Andrew DahlPresident Ophthalmology Consultants What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Lumigan X EU Committee Recomendation

October 27, 2009

EU committee backs marketing approval of Lumigan | www.pharmabiz.com

The Committee for Medicinal Products for Human Use (CHMP) of the European Union has recommended granting a Marketing Authorization for a new version of Allergan's Lumigan (bimatoprost ophthalmic solution). This new version will be marketed as Lumigan-X after approval. Lumigan X offers Allergan a new formulation to compete against generic versions of its glaucoma drug Lumigan after patent protection for Lumigan expires shortly.There will be very limited demand for Lumigan-X.

Steve Rubinstein, Optometrist

Steve RubinsteinOptometristSound Shore Vision Care What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Contact Lens Nirvana: Hyperpermeable One Day

October 2, 2009

Hobby assists Irish strategy | www.opticianonline.net

 This article describes resources being put into place to mass produce the first commercially available silicon hydrogel one day disposable contact lens in the USA by Johnson & Johnson's Vistakon division.

Steve Rubinstein, Optometrist

Steve RubinsteinOptometristSound Shore Vision Care What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Alcon, Novartis (Ciba Vision), Astra-Zeneca working on ocular medications?

July 23, 2009

Alcon Signs Agreement With AstraZeneca On Eye Drug Development | www.pharmaceutical-business-review.com

This agreement seems to allow Alcon Laboratories, Inc and Astra-Zeneca  to work together to produce ocular medications. What it doesn't say is that they can also use Ciba Vision's resources in the near future.

Steve Rubinstein, Optometrist

Steve RubinsteinOptometristSound Shore Vision Care What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

A drop in the price of OTC allergy eye drops?

July 5, 2009

Sun Pharmaceutical gets tentative nod from USFDA for ‘Optivar Solution’ | Top News | www.topnews.in

By adding a third OTC antihistamine eye drop to the mix the price competition should make the cost to the consumer decrease.

Rahul KhuranaClinical Instructor of Ophthalmology UNIVERSITY OF CALIFORNIA, SAN FRANCISCO What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Promising Eye Drop for Dry Age-Related Macular Degeneration.

April 15, 2009

Eye drop treatment for dry AMD shows promise in Phase 2 trial | www.othera.com

Othera Pharmaceuticals, Inc. announced positive interim data results from its Phase 2 trial of OT-551 in treating geographic atrophy (GA) in dry AMD. OT-551 is a topically-dosed, patented small molecule that acts on oxidative stress and disease-induced inflammation. The 12-month findings from the two-year trial suggest an emerging trend for reducing moderate vision loss in 137 patients with GA who were treated with OT-551 compared with placebo.

Steve Rubinstein, Optometrist

Steve RubinsteinOptometristSound Shore Vision Care What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Laser Vision Correction for Presbyopia is here!

April 6, 2009

Presbyopic laser vision correction reduces spectacle dependence in pseudophakes | www.modernmedicine.com

The missing element in LVC today is real multifocal correction to deal with a the large population of baby boomers that are finding a need for a different correction for distance vision than near vision(most people over 40 years of age). As of now we have only two options for adults: 1) two eyes corrected for distance vision and reading glasses or 2) mono-vision, one eye corrected for near, and the other corrected for distance vision. We currently have the ability to create mulitfocal spectacle lenses, and multifocal contact lenses. Johnson & Johnson's Vistakon just released a new Acuvue for Presbyopia in March 2009, CooperVision and Bausch & Lomb have both had multifocal contact lenses for years.

Rahul KhuranaClinical Instructor of Ophthalmology UNIVERSITY OF CALIFORNIA, SAN FRANCISCO What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Alcon's Potential New Glaucoma Treatment: Anecortave Acetate.

April 5, 2009

Arch Ophthalmol -- Abstract: Reduction of Intraocular Pressure With Anecortave Acetate in Eyes With Ocular Steroid Injection-Related Glaucoma, February 2009, Robin et al. 127 (2): 173 | archopht.ama-assn.org

Alcon (ACL) is working on an intriguing new treatment modality for glaucoma.  Unlike previous drops that require daily dosing, this medication only needs to be given every three months. This small case series reports promising results where anecortave acetate lowers intraocular pressure in steroid induced ocular hypertension.

Rahul KhuranaClinical Instructor of Ophthalmology UNIVERSITY OF CALIFORNIA, SAN FRANCISCO What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Rho Kinase Inibitors could be a New Approach in Glaucoma Management.

April 5, 2009

Arch Ophthalmol -- Abstract: Intraocular Pressure-Lowering Effects and Safety of Topical Administration of a Selective ROCK Inhibitor, SNJ-1656, in Healthy Volunteers, March 2008, Tanihara et al. 126 (3): 309 | archopht.ama-assn.org

Rho Kinase Inhibitors could be the next big step in Glaucoma Management.  Rho kinase inhibition has been studied in various animal models to lower intraocular pressure; and this is the first clinical report involving healthy human subjects.  The potential of this class is large in a field where there have not been many developments recently.

Steve Rubinstein, Optometrist

Steve RubinsteinOptometristSound Shore Vision Care What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Will contact lens solutions cost more to ship and store?

November 13, 2008

Eye Infection Epidemic Traced To Reduced Antifungal Properties Of Contact Lens Solution In High Temperatures | www.medicalnewstoday.com

A new study in Archives of Ophthalmology, November 2008 indicates that a reason for the large number of infections from Bausch & Lomb's Renu Moisture Loc solution was due to poor temperature control reducing antifungal and antimicrobial efficacy.

Steve Rubinstein, Optometrist

Steve RubinsteinOptometristSound Shore Vision Care What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Lasik, Pharma, and Cataracts...are they recession proof?

November 4, 2008

Value Stocks in the Eye of the Storm? | news.morningstar.com

The article goes into the four major eye care markets that have a mix of reimbursed, and consumer driven areas. It describes the issues I face as a provider of these products. 

Page : 12345678910Next1 to 10 of 165

Leading institutions connect with members of the Healthcare councils through GLG

Most Popular Healthcare News